Watch Total Prescribing Information OPDIVO® (nivolumab) is indicated for the treatment of Grownup patients with classical Hodgkin lymphoma (cHL) which includes relapsed or progressed following autologous hematopoietic stem mobile transplantation (HSCT) and brentuximab vedotin or following 3 or more traces of systemic therapy that includes autologo